Safety and Pharmacokinetics of Kovacaine Nasal Spray (24 Hour Blood Collection)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Anesthesia

Interventions

DRUG

Tetracaine HCl 3% and Oxymetazoline HCl 0.05%

1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl (para-butylaminobenzoic acid or PABA is active metabolite)

Trial Locations (1)

Jean Brown Research, Salt Lake City